%PDF-1.5 It is used either by mouth or injection into a vein.. Common side effects include headache, vomiting, sleepiness, loss of appetite, cough, rash, and joint pain. A randomized, controlled trialThe Association of an Increasing Waist Circumference and Risk of Incident Low Physical Function in Adults with Knee OsteoarthritisIdentifying Research Priorities among Patients and Families of Children with Rheumatic Diseases Living in the United StatesThe Risk and Consequences of Vertebral Fracture in Patients with Ankylosing Spondylitis: A Population-based Data Linkage StudyThe Association of an Increasing Waist Circumference and Risk of Incident Low Physical Function in Adults with Knee OsteoarthritisIdentifying Research Priorities among Patients and Families of Children with Rheumatic Diseases Living in the United StatesThe Risk and Consequences of Vertebral Fracture in Patients with Ankylosing Spondylitis: A Population-based Data Linkage Study Mesna clearly inhibited the toxic properties of acrolein. Controlled trial of prednisone and cytotoxic drugsImmunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamideMycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisIntravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortalityA multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaCyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung diseaseEffects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis.

CYC was administered only intravenously in 928 patients (90.6%), exclusively orally in 49 patients (4.8%), and by both routes in 41 patients (4%).

<> After in vivo application of Mesna and cyclophosphamide to rats, however, a lower yield of mutagens in the excreted urine was observed than after application of cyclophosphamide only.We use cookies to help provide and enhance our service and tailor content and ads. eCollection 2017 Sep.Bleloch JS, Ballim RD, Kimani S, Parkes J, Panieri E, Willmer T, Prince S.Ther Adv Med Oncol. CYC: cyclophosphamide.Cox proportional hazard regression analysis of predisposing factors for hemorrhagic cystitis occurrence.In our study, we identified 17 hemorrhagic cystitis and 2 bladder cancers in patients treated with CYC in 4224 patient-years of exposure.

Prospective studies are needed to determine the uroprotective effect of mesna.Thank you for your interest in spreading the word about The Journal of Rheumatology.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. eCollection 2015. endobj <>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.44 841.68] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> Mesna (sodium 2-mercaptoethane sulfonate) decreases the urotoxieity by scavenging the toxic metabolite acrolein. %����

P values ≤ 0.05 were considered significant. Regimen 21 day cycle for 7 cycles Drug Dose Days Administration Mesna 500mg/m2 1 Intravenous infusion in 100ml sodium chloride 0.9% over 15minutes Cyclophosphamide 21500mg/m 1 Intravenous infusion in 1000ml sodium 2017 Dec;83(12):2605-2614. doi: 10.1111/bcp.13388.

The database was searched for patients with SLE, SSc, vasculitis, and other autoimmune diseases treated with CYC. A long-term follow-upTherapy of lupus nephritis. Cyclophosphamide is an effective antitumor agent with considerable side effects such as urotoxicity and carcinogenicity.

Optimum dosage and scheduling remain to be determined; studies suggest that a fractionated dosage schedule provides antineoplastic activity with tolerable toxicity.

�J�b�� �ΗO��S�����j���N@�*�m�L����>!E;7gߒ��Б{t�zT���W}<1��޲�؀M� Ifosfamide, used in combination with mesna for uroprotection, provides a useful therapeutic option for the management of patients with testicular cancer, soft tissue sarcomas, or high-grade malignant lymphomas. The median cumulative dose of CYC in our cystitis patients was 10 g (range 2.5–180).Hemorrhagic cystitis incidence was similar in patients treated with mesna [with vs without mesna 9/585 (1.53%) vs 8/424 (1.88%), respectively, p = 0.08]. However, we cannot suggest that mesna has a protective effect for hemorrhagic cystitis. Where ifosfamide is used as a 24-hour infusion: Mesna can be used as a concurrent infusion.An initial 20% (w/w) of the total ifosfamide dose is given as an i.v. Show all parts of this monograph; Indications and dose; Side-effects; Allergy and cross-sensitivity; Pregnancy ; Effect on laboratory tests; Directions for administration; Medicinal forms; Indications and dose. However, the incidence of hemorrhagic cystitis varies in different studies in the rheumatology literature.